These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1848 related articles for article (PubMed ID: 28393575)

  • 1. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy.
    Oellerich M; Schütz E; Beck J; Walson PD
    Ther Drug Monit; 2019 Apr; 41(2):115-120. PubMed ID: 30883505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
    Anderson CJ; Yang H; Parsons J; Ahrens WA; Jagosky MH; Hsu JH; Patt JC; Kneisl JS; Steuerwald NM
    Clin Orthop Relat Res; 2024 Jun; ():. PubMed ID: 38905450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.
    Weiss GJ; Beck J; Braun DP; Bornemann-Kolatzki K; Barilla H; Cubello R; Quan W; Sangal A; Khemka V; Waypa J; Mitchell WM; Urnovitz H; Schütz E
    Clin Cancer Res; 2017 Sep; 23(17):5074-5081. PubMed ID: 28320758
    [No Abstract]   [Full Text] [Related]  

  • 7. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
    Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
    Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
    Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
    Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
    Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
    Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
    Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
    EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
    Chen X; Chang CW; Spoerke JM; Yoh KE; Kapoor V; Baudo C; Aimi J; Yu M; Liang-Chu MMY; Suttmann R; Huw LY; Gendreau S; Cummings C; Lackner MR
    Clin Cancer Res; 2019 Apr; 25(7):2254-2263. PubMed ID: 30617129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
    Schweizer MT; Gulati R; Beightol M; Konnick EQ; Cheng HH; Klemfuss N; De Sarkar N; Yu EY; Montgomery RB; Nelson PS; Pritchard CC
    Prostate; 2019 May; 79(7):701-708. PubMed ID: 30865311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.
    González-Billalabeitia E; Conteduca V; Wetterskog D; Jayaram A; Attard G
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):195-205. PubMed ID: 30413805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 93.